secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-021953
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Phase 2 trial shows frataxin increases in skin and buccal cells; Q1 net loss $6.5M
--------------------------------------------------------------------------------

- Median placebo-adjusted frataxin increase from baseline: 3.5 pg/µg in skin, 0.9 pg/µg in buccal cells at day 14.
- CTI-1601 generally well tolerated; one severe allergic reaction led to withdrawal; 8 of 9 completed the cohort.
- Data submitted to FDA; meeting scheduled Q2 2023; program update expected Q3 2023.
- Q1 2023 net loss $6.5M ($0.15/diluted share) vs $8.9M ($0.49) in Q1 2022; cash $111.5M as of March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/0000950170-23-021953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/lrmr-20230515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer